Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597 ·Status: TERMINATED ·Phase: PHASE2

Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

NCT07188428 ·Status: COMPLETED

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

NCT04626024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT05143840 ·Status: RECRUITING ·Phase: PHASE2

Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)

NCT01394666 ·Status: COMPLETED

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

NCT03216070 ·Status: UNKNOWN ·Phase: PHASE4

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

NCT00084916 ·Status: COMPLETED ·Phase: PHASE2

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00093470 ·Status: COMPLETED ·Phase: PHASE3

Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy

NCT06692803 ·Status: COMPLETED

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT05367765 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

NCT03610971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019 ·Status: NOT_YET_RECRUITING

A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan

NCT07150793 ·Status: COMPLETED

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

NCT06368414 ·Status: RECRUITING ·Phase: PHASE2

MEOI and HRQoL in CLL Patients Treated With BTKis

NCT04938141 ·Status: COMPLETED

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

NCT06121765 ·Status: NOT_YET_RECRUITING

Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia

NCT05893836 ·Status: COMPLETED

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

NCT00123474 ·Status: COMPLETED ·Phase: PHASE3

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740 ·Status: COMPLETED ·Phase: PHASE2

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase

NCT00514969 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

NCT01522469 ·Status: COMPLETED ·Phase: PHASE2

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT04694560 ·Status: WITHDRAWN

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

NCT00006053 ·Status: COMPLETED ·Phase: PHASE2

Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia

NCT03131986 ·Status: UNKNOWN